HBL - Hadasit Bio-Holdings Ltd.
(the “Company”)
July 14, 2015
To: To:
Israel Securities Authority Tel Aviv Stock Exchange Ltd.
www.isa.gov.il www.tase.co.il
Re: Receipt of US Patent of CellCure Neurosciences
The Company is pleased to announce that Cell Cure Neurosciences Ltd., a company held 21.2% by the Company (hereinafter: “Cell Cure”) has received a US patent entitled:
METHODS OF CULTURING EMBRYONIC STEM CELLS AND CONTROLLED DIFFERENTIATION (US Patent No. 9,080,147) (hereinafter: the “Patent”).
The Patent is owned by ES Cell International, which granted Cell Cure an exclusive license to use the Patent.
The patent relates to methods of differentiation and maturation of embryonic stem cells and is important for protecting Cell Cure’s technology of generating mature cells such as neurons and retinal cells for transplantation and regeneration.
The Patent is valid until June 20, 2021.
Sincerely,
HBL - Hadasit Bio-Holdings Ltd.
By: Ms. Tamar Kfir, CEO
| 
